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Abstract: The present work provides an overview about the potentiality of differently 
substituted 3-amidocoumarins in the neurodegenerative diseases. The inhibitory 
activity of MAOs, as well as the reversibility of the inhibition, the neuroprotective effects 
on neuronal cells against H2O2, the antioxidant effect measured by DPPH free radical 
scavenging of 3-amidocoumarins, and the cross through blood-brain barrier for the 
most potent derivatives, have been evaluated. Many of these derivatives proved to be 
capable of selectively inhibiting the MAO-B isoenzyme. Substitution at position 4 with a 
hydroxyl group leads to a loss of activity of the 3-benzamidocoumarins against this 
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enzyme, but favours their neuroprotective activity against H2O2. Regarding the 3-
heteroarylamide derivatives, it was the nature of the heterocycle that determined its 
neuroprotective effects. Although none of the studied derivatives violated the 
theoretical Lipinski's rules, the parallel artificial membrane permeation assay showed 
that not every compound could efficiently cross the blood-brain barrier. However, this 
new scaffold presented, in general, desirable properties for the development of 
potential drug candidates against neurodegenerative diseases. 
 
Introduction 
Neurodegenerative diseases (ND) are characterized by a decrease in the number of 
cells of certain neuronal populations, and are clinically reflected by the appearance of 
specific symptoms, such as modification in the control and coordination of movement in 
Parkinson's disease (PD) or alterations in the language and memory processes in 
Alzheimer's disease (AD).[1] Their chronic course produces a gradual but steady 
deterioration whose last step is death.[2] Because of this, as the disease progresses, it 
is eroding the quality of life of patients.[3] Therefore, the development of effective 
neuroprotective therapies that slow down or stop disease’s progression in the earliest 
stages is one of the main goals of the researchers in this area.[4] 
At the cellular level, PD is related to excess production of reactive oxygen species 
(ROS), to alterations in catecholamine metabolism, to modifications in mitochondrial 
electron transporter chain (METC) function or to enhancement of iron deposition in the 
SNpc.[5] The failure of normal cellular processes that occur in relation to the aging are 
also believed to contribute to the increased vulnerability of dopaminergic (DA) 
neurons.[6] Although the precise mechanism corresponding to ROS generation related 
to PD is still unknown, the major sources of oxidative stress generated by the DA 
neurons are DA metabolism, mitochondrial dysfunction, and neuroinflammation.[7] 
Metabolism of DA by monoamine oxidase (MAO) yields hydrogen peroxide (H2O2), an 
oxygen radical that leads to cytotoxicity through peroxidation of lipid membranes. 
Selegiline and rasagiline, two selective MAO-B inhibitors are currently used to retard 
the symptoms in PD because they increase the dopamine levels and may exert 
neuroprotective effects. Inhibition of MAO-B reduces oxygen radical generation 
although new neuroprotective functions independently of inhibiting MAO activity have 
been reported for these drugs.[8] The occurrence of oxidative stress in PD patients is 
supported by postmortem studies and by preclinical studies showing the ability of 
oxidizing toxins to induce cell death in the substantia nigra.[9] Accordingly, antioxidants 
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that scavenge free radicals and reactive species such as tocopherol and ascorbate 
may have beneficial therapeutic effects in PD by preventing the onset of apoptotic cell 
death and neuronal degeneration of the dopaminergic nigrostriatal pathway.[10] 
Nonetheless, all approved PD pharmacotherapies have limited efficacy, do not prevent 
the progression of the disease, and are associated with adverse motor and non-motor 
side effects.[11] Accordingly, there is an urgent need to develop novel therapies that are 
superior to the current therapies. 
Since the beginning of medicine, the nature has played a key role as source of 
inspiration in the development of drugs with important biological activities. Coumarins 
(2H-1-benzopyran-2-one), common metabolites in plants (also detected in 
microorganisms and animal sources),[12] have shown great interest, in particular due to 
several pharmacological activities that they may display.[13] The pharmacological and 
biochemical properties, and therapeutic applications of simple coumarins depend on 
the various substitutions of the scaffold.[13] Of thousands of different coumarins 
currently existent, some natural or obtained by chemical synthesis have been 
evaluated in many different pharmacological targets of great interest in the field of 
medicinal chemistry.[14] Therefore, there are coumarins as antioxidants and anti-
inflammatories,[15] neuroprotective agents,[16,17] antidepressants,[18] anticonvulsants,[19] 
antibacterials,[20] antivirals,[21] anticancer agents,[22,23] anticoagulants,[24] 
antihypertensives[25] and enzyme inhibitors,[26-33] among others. More recently it has 
been found that simple coumarins, usually substituted at positions 3, 4, 6, 7 or 8 have 
properties such as MAO inhibitors, which makes them an interesting option in the 
search for new drugs for the treatment of ND.[27-33] In recent years, simple coumarins 
substituted at positions 3 or 4 have been described by exhibiting activity as inhibitors of 
cholinesterases (ChE), both acetylcholinesterase (AChE) and butyrylcholinesterase 
(BuChE). The planarity and aromaticity of these derivatives proved to be essential for 
the activity. The substitution at these positions of the coumarin ring also allowed 
interesting derivatives resulting β-secretase 1 (BACE-1) inhibitors.[26,29] All these 
properties encouraged our group to study differently substituted coumarins as lead 
compounds with potential interest for ND’s therapeutics. Therefore, our research group 
has been working, in recent years, in the study of 3-substituted coumarins with activity 
on different targets involved in ND. The introduction of an amide group as a linker 
between the coumarin skeleton and a phenyl at position 3 has allowed the obtaining of 
coumarins with dual activity as MAO and ChE inhibitors.[29] The introduction of hydroxyl 
groups in the molecule enhanced their antioxidant properties.[34] 
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Taking into account the background of our research group (Figure 1),[28-33] the present 
work provides an overview about the potential of differently substituted 3-
amidocoumarins as inhibitors of MAO, antioxidants and neuroprotective agents. The 
influence on the activity of the different nature of the amides introduced at position 3 
and the introduction of a hydroxyl group at position 4 of the substituted 3-
amidocoumarins, is herein studied. 
 
 
Figure 1.The rational for the design of the studied compounds. 
 
 
Results and Discussion 
Chemistry 
The described derivatives were efficiently synthesized according to the protocol 
outlined in Scheme 1. Coumarins 1-17 were prepared starting from the 3-
aminocoumarin, commercially available, or from the 3-amino-4-hydroxycoumarin, 
which was prepared trough the reduction of the commercially available 3-nitro-4-
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hydroxycoumarin, in ethanol, with Pd/C as catalyst, in H2 atmosphere, for 5 hours, with 
a yield of 90%.[35,36] An acylation of the 3-aminocoumarins with the conveniently 
substituted acid chloride, using pyridine in dichloromethane, from 0 °C to room 
temperature, afforded the differently 3-substituted coumarins (1-17) in yields between 
80 and 90%.[32,37-42] The reaction conditions and chemical characterization of the new 
compounds are detailed in the experimental section. 
 
 
Scheme 1. Reagents and conditions:(a) H2, EtOH, Pd/C, r.t., 5 h; (b) pyridine, 
dichloromethane, 0 °C to r.t., overnight. 
 
Pharmacology  
MAO in vitro inhibition 
The biological evaluation of the test drugs on hMAO activity was investigated by 
measuring their effects on the production of H2O2 from p-tyramine (a common 
substrate for hMAO-A and hMAO-B), using the Amplex® Red MAO assay kit and 
microsomal MAO isoforms prepared from insect cells (BTI-TN-5B1-4) infected with 
recombinant baculovirus containing cDNA inserts for hMAO-A or hMAO-B.[43] The 
production of H2O2 catalysed by the two MAO isoforms can be detected using 10-
acetyl-3,7-dihydroxyphenoxazine (Amplex® Red reagent), a non fluorescent and highly 
sensitive probe that reacts with H2O2 in the presence of horseradish peroxidase to 
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were unable to react directly with the Amplex® Red reagent, which indicates that these 
drugs do not interfere with the measurements. On the other hand, in the experiments 
and under the experimental conditions, hMAO-A displayed a Michaelis constant (Km) 
equal to 457.17 ± 38.62 μM and a maximum reaction velocity (Vmax) in the control 
group of 185.67 ± 12.06 (nmol p-tyramine/min)/mg protein, whereas hMAO-B showed a 
Km of 220.33 ± 32.80 μM and Vmax of 24.32 ± 1.97 (nmol p-tyramine/min)/mg protein (n 
= 5). Most tested compounds concentration-dependently inhibited this enzymatic 
control activity. The experimental IC50 results are expressed in Table 1. 
 
Table 1. In vitro hMAO-A and hMAO-B inhibitory activity of the synthesized derivatives 
1-17 and reference compound.[a] 
Comp. IC50 hMAO-A (µM) IC50 hMAO-B (µM) S. I.
[b] 
1 * 0.76 ± 0.05 > 131.6[d] 
2 * * - 
3 * * - 
4 * * - 
5 * * - 
6 * 36.91 ± 2.48 > 2.7[d] 
7 * * - 
8 * 19.00 ± 1.27 > 5.3[d] 
9 * * - 
10 * ** - 
11 * ** - 
12 * 2.27 ± 0.15 > 44.1[d] 
13 * 15.50 ± 1.04 > 6.5[d] 
14 * 21.11 ± 1.42 > 4.7[d] 
15 * * - 
16 * 49.96 ± 3.35 > 2.0[d] 
17 * 22.47 ± 1.51 > 4.5[d] 
Selegiline 67.25 ± 1.02[c] 0.019 ± 0.0013 3,539 
Rasagiline 16.44±0.85 0.069 ± 0.004 238 
Isatin * 33.07 ± 1.47 > 3.0 
[a] Each IC50 value is the mean ± S.E.M. from five experiments (n = 5). 
[b] Selectivity 
index: MAO-B selectivity ratios [IC50 (MAO-A)]/[IC50 (MAO-B)] for inhibitory effects of 
both new compounds and reference inhibitors. [c] p <0.01 regarding the corresponding 
IC50 obtained against MAO-B as determined by ANOVA/Dunnett’s. 
[d] Values obtained 
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under the assumption that the corresponding IC50 against either MAO-A or MAO-B is 
major than 100 µM. * Inactive at 100 µM (highest concentration tested). ** 100 µM 
inhibits enzymatic activity by approximately 50-55%. At higher concentrations the 
compounds precipitate. 
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As shown in Table 1, many of the studied compounds displayed selective inhibitory 
activity against hMAO-B in the micromolar range, being the compound 1 the most 
active derivative of the series (IC50 = 0.76 µM). Regarding the 3-benzamidocoumarins 
and comparing with previously published results,[29] it was observed that, in general, the 
introduction of a hydroxyl group at position 4 of the coumarin scaffold resulted in a loss 
of activity against hMAO-B, lacking this activity the derivatives 2-5, 7 and 9. In fact, 
from this series, only compound 6 presented hMAO-B inhibitory activity (IC50 = 36.91 
µM). Identical response was observed when the 3-substituent is a heteroarylamide 
group, with hydroxyl group at position 4. In general, it was produced a decrease (in the 
case of the thiophenyl derivative) or loss of hMAO activity (in the case of the furanyl 
and pyridyl derivatives). Moreover, the nature of the heterocycle determined the 
activity, and the compounds having a thiophene ring on their structure (compounds 12 
and 13) proved to be active against hMAO-B (IC50 = 2.27 µM andIC50 = 15.50 µM, 
respectively), whereas those with a furan ring on it (compounds 10 and 11) lack this 
activity. Compounds bearing a pyridine ring on their structure (compounds 14 and 15), 
follow the general rule of the hydroxylated compounds. Compound 14, without hydroxyl 
group at position 4, proved to display activity against hMAO-B (IC50 = 21.11 µM) while 
compound 15, with a hydroxyl group at position 4, did not. For derivatives with the 
amide group at position 3 linked to a cyclohexane group (compounds 16 and 17) it was 
observed that the introduction of the hydroxyl at position 4 improved the activity against 
hMAO-B (IC50 = 49.96 µM and IC50 = 22.47 µM, respectively). This proved to be the 
only case in which the introduction of a hydroxyl group at position 4 has led to a slightly 
improvement of the activity. 
 
Reversibility assay 
Reversibility experiments were performed to evaluate the type of inhibition of 
derivatives 1, 12, 14 and 17 (Table 2). These compounds were selected based on their 
structure and activity against hMAO-B. An effective dilution method was used, and 
selegiline (irreversible inhibitor) and isatin (reversible inhibitor) were taken are 
standards.[44,45] 
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Table 2. Reversibility results of hMAO-B inhibition studied for derivatives 1, 12, 14 and 
17, and reference inhibitors. 
Compounds Slope (AUF/t) [%]a 
1 41.511 ± 2.785 
12 63.036 ± 4.229 
14 38.429 ± 2.578 
17 67.759 ± 4.545 
Selegiline 3.208 ± 0.212 
Isatin 88.634 ± 5.946 
a Percentage values represent the mean ± SEM 
of three experiments (n = 3) relative to control; 
data show recovery of hMAO-B activity after 
dilution. 
 
hMAO-B inhibition was proved to be reversible in the presence of compounds 1, 12, 14 
and 17, being their degree of reversibility lower than that described for isatin (reversible 
reference compound).  
 
Neuronal survival 
Compounds 1-17 were studied by in vitro test with the goal of evaluating their 
neuroprotective potential in addition to their MAO activity and assessed their effect on 
the oxidative stress. Firstly, in order to discard a possible cytotoxic effect of compounds 
1-17 against rat cortical neurons, the cell viability was assessed at 24 h after treatment 
with 100 µM concentration of the new compounds. MTT test, which determines the 
cells dehydrogenase enzyme activity, was used. Hence, cells that are metabolically 
impaired reduce less MTT than “healthy cells”. When compared to the control (1% 
DMSO) only compounds 10 and 11 induced a significant reduction in viability at 100 
µM post-treatment, while the rest of the compounds were void of any cytotoxicity 
(graphic 1). 
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Graphic 1. Cytotoxicity of compounds 1-17 (100 µM) on cortical neurons treated. 
Results are expressed as mean ± S.E.M from at least 5 experiments. * P <0.05, ** P 
<0.001 versus the corresponding viability obtained in the control group treated with 
DMSO. 
 
Then, the neuroprotective effect of compounds 1-17 was assessed in cultured rat 
cortical neurons exposed to H2O2. Neurons incubated or not with compounds 1-17 (100 
μM), were exposed to H2O2 (30 μM) at the same time point and incubated for 24 hours. 
The toxin treatment group in the cell viability assays showed a significant difference in 
production of toxicity compared to those treated only with DMSO. 
The results obtained by studying the possible neuroprotective effects of our molecules 
against the effects of H2O2 in the cells are shown in graphic 2.  
From the 3-benzamidocoumarins 1-9, the most promising results against the effects of 
H2O2 (graphic 2) corresponded, in general, to the derivatives presenting an hydroxyl 
group at position 4 of the coumarin scaffold and a single substituent in para position of 
the benzamide at position 3 (compounds 3, 7 and 9). In the case of 3-heteroarylamido- 
and 3-cyclohexanecarboxamidocoumarins 10-17 it was shown that the derivatives 
having a nicotinamide group at position 3 of the coumarin scaffold (compounds 14 and 
15) exerted a statistically significant neuroprotection, whereas when the pyridine ring 
was substituted for a cyclohexane, thiophene or furan group, the compounds proved to 
be inactive against H2O2. Under these conditions, rasagiline (5µM) did not display 
significant neuroprotection. In view of these results it is possible that other mechanisms 
beyond MAO inhibition may be involved in the neuroprotective activity of these 
derivatives. 
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Graphic 2. Neuroprotective effects of compounds 1-17 (100 µM) and rasagiline (5 µM) 
on cortical neurons treated with H2O2. Results are expressed as mean ± S.E.M from at 
least 5 experiments. # P <0.05 versus the group treated only with DMSO. * P <0.05, ** 
P <0.001 versus the corresponding viability obtained in the control group treated with 
H2O2 in addition to DMSO. 
 
Neuroprotection exerted by these compounds is concentration dependent. Therefore a 
decrease in the neuroprotection is observed when cultured rat cortical neurons were 
exposed to H2O2 but treated with compounds 1-17 at 10 µM concentration. No 
significant differences were found for neurons treated with any compounds and 
exposed to H2O2 (Table 3). 
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Table 3. Viability of the cells (expressed in %) treated with compounds 1-17 (at 10 µM 
and 100 µM). 
Compounds 
Viability (%) 
at 10 µM 
Viability (%) 
at 100 µM 
DMSO + H2O2 72.21 ± 1.71 78.29 ± 1.68 
1 73.33 ± 3.06ns 79.10 ± 1.00ns 
2 67.96 ± 2.12ns 73.65 ± 3.33ns 
3 63.80 ± 2.57ns 104.41 ± 6.26** 
4 69.69 ± 3.77ns 85.88 ± 6.70ns 
5 71.73 ± 4.34ns 83.16 ± 5.86ns 
6 78.49 ± 6.00ns 76.33 ± 2.27ns 
7 79.43 ± 6.54ns 102.40 ± 3.76** 
8 71.40 ± 7.32ns 99.05 ± 5.20* 
9 72.24 ± 3.96ns 101.89 ± 0.75** 
10 72.44 ± 6.40ns 83.61 ± 2.75ns 
11 70.61 ± 7.28ns 83.10 ± 3.85ns 
12 68.19 ± 3.90ns 91.31 ± 5.26ns 
13 71.27 ± 4.74ns 86.25 ± 3.26ns 
14 67.88 ± 6.32ns 100.60 ± 10.56** 
15 73.62 ± 6.44ns 106.07 ± 6.26** 
16 72.90 ± 0.67ns 84.86 ± 6.27ns 
17 74.20 ± 3.57ns 80.65 ± 2.98ns 
ns no significant differences were found with the control group (DMSO and H2O2). * P 
<0.05, ** P <0.001 versus the corresponding viability obtained in the control group 
treated with H2O2 in addition to DMSO. 
 
 
DPPH scavenging  
Under normal conditions, free radicals are rapidly neutralized in the mitochondria, but 
over the years, this neutralization is no longer effective and dysfunction and even cell 
death occurs. We studied the DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging 
activity of those compounds showing best neuroprotective effects, in cells treated with 
H2O2 (compounds 3, 7, 9, 14 and 15). As it can be seen in graphic 3, most of the 
studied compounds exerted free radical scavenging, being compounds 3 and 7 (100 
µM) the most active derivatives, which showed a scavenging activity slightly higher 
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than 50%. These are also two of the best compounds of the series of 3-
benzamidocoumarins as neuroprotective agents against H2O2. By contrast, for the 
series of 3-nicotinamidocoumarins, compounds 14 and 15, only when a hydroxyl group 
is present at position 4 (compound 15) a free radical scavenging activity by 
approximately 20% was observed. Therefore, the presence of a hydroxyl group, in this 
specific case at position 4, seems to be critical for neutralization of free radicals by 
these derivatives. 
 
Graphic 3. DPPH scavenging activity of coumarin derivatives 3, 7, 9, 14, 15 and 
vitamin C (positive control). 
 
 
In vitro blood-brain barrier permeation assay 
A basic condition of any compound to act on neurodegenerative processes is to 
penetrate into the brain, that is, to be able of crossing the blood-brain barrier (BBB). To 
examine the capability of our compounds to pass this barrier, we select compounds 3, 
12, 14 and 15, some of the most active derivatives as MAO inhibitors and/or 
neuroprotective agents, and used a parallel artificial membrane model (PAMPA).[46] 
This is a fairly easy and successful method to predict the passive central nervous 
system (CNS) permeation, which had been previously optimized in order to be applied 
to investigational compounds with limited aqueous solubility.[47-49] Experimental results 
are represented in table 4. 
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Table 4. In vitro evaluation of the CNS penetration "experimental permeability (Pe 10-6 
cm s-1)" using the PAMPA methodology. Results are expressed as the mean of the 
experimental prediction through at least 3 independent experiments ± SD. 
Compounds Pe Prediction 
3 7.4 ± 0.01 SNC - 
12 44.2 ± 2.1 SNC + 
14 20.2 ± 0.4 SNC + 
15 9.3 ± 0.1 SNC +/- 
Verapamil 14.8 ± 0.1 SNC + 
 
The permeability of the compounds through a lipid extract of porcine brain were 
determined using a mixture 70:30 of phosphate buffered saline solution and ethanol 
(PBS:EtOH). In each experiment 10 commercial drugs were also evaluated for assay 
validation. The graphic representation of experimental permeability vs. reported values 
of such well-known drugs gave a lineal correlation, Pe (exptl) = 0.72 Pe (bibl) + 6.70 
(R2 = 0.80). From this equation and taking into account the described limits for BBB 
permeation, we established that compounds with permeability values above 9.6·10-6 
cm s-1 could penetrate into the CNS by passive diffusion (CNS+), whereas products 
with Pe below 8.1·10-6 cm s-1 could not enter (CNS-). Between these values, the CNS 
permeation was considered as uncertain (CNS+/-). Therefore, from the selected 
compounds, compounds 12 and 14 (Pe = 44.2·10-6 cm s-1 and Pe = 20.2·10-6 cm s-1, 
respectively) would be able to cross BBB and reach their therapeutic targets. In 
addition, both compounds showed a higher Pe value than verapamil (Pe = 14.8·10-6 cm 
s-1), which is generally used as a standard of high permeability. In the case of 
compound 15, the passage through the BBB is doubtful (Pe = 9.3·10-6 cm s-1). 
Theoretical evaluation of ADME-related physicochemical/structural parameters  
In order to better understand the overall properties and the drug-like characteristics of 
compounds 1-17, the lipophilicity (expressed as the octanol/water partition coefficient 
and herein called logP), and the theoretical prediction of other ADME properties 
(molecular weight, TPSA, number of hydrogen donors and acceptors, and volume) 
were carried out with Molinspiration calculation software and are presented in the 
supplementary data.[50,51] 
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From the data presented in the supplementary data, it is significant that all the 
described derivatives possess logP values compatible with those required to cross 
membranes. Although TPSA (described to be a predictive indicator of membrane 
penetration) of selegiline is too different of those found to the studied compounds, all 
values were found to be in the desirable range. In addition, it can be observed that no 
violations of Lipinski’s rule (molecular weight, logP, number of hydrogen donors and 
acceptors) were found. The studied compounds, as MAO inhibitors and 
neuroprotective agents, have to pass different membranes and reach the CNS. The 
obtained information supports the potential of these derivatives as potential drug 
candidates. The theoretical information obtained is partially in accordance to the 
experimental in vitro BBB permeation assay. The combination of both results can help 
to better understand the drug likeness of this series of compounds. 
 
Conclusions 
In this study, a general and efficient synthesis of a new series of 3-amidocoumarins 
was developed, using an amidation reaction as key step. Determination of hMAO 
isoform activity was carried out, and many of the compounds exhibited selectivity for 
the hMAO-B isoenzyme with activity in the range of nanomolar (compound 1) or 
micromolar concentrations (compounds 6, 8, 12-14, 16 and 17). Neuroprotective 
effects against H2O2 were also studied. For the series of 3-benzamidocoumarins, the 
most promising results in cells treated with H2O2 corresponded, in general, to the 
derivatives that present a substituent in para position of the benzamide ring, 
additionally to a hydroxyl group at position 4 of the coumarin scaffold (compounds 3, 7 
and 9). For the series of 3-heteroarylamidocoumarins, derivatives having a 
nicotinamide group at position 3 of the coumarin scaffold (compounds 14 and 15) 
exerted the most remarkable neuroprotection. Most of the selected derivatives exerting 
neuroprotection showed also DPPH scavenging activity (excepting compound 14, with 
no hydroxyl groups on its structure). Additionally, prediction of BBB partitioning through 
a PAMPA assay showed the potential of this type of compounds to cross the BBB and 
act in the CNS. From the four studied compounds, those without a hydroxyl group at 
position 4 proved to have better facility to cross the BBB (compounds 12 and 14). 
Compound 15 proved to partially be able to cross biological barriers. In addition, 
prediction of ADME-related physicochemical/structural parameters provided a 
preliminary indication of the potential of this family of compounds to possess the desire 
drug ability properties. The results encourage us to further explore the potential of this 
chemical family as potential drug candidates for the treatment of Parkinson’s disease. 
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Experimental Section 
Chemistry 
Starting materials and reagents were obtained from commercial suppliers and were 
used without further purification (Sigma-Aldrich). Melting points (mp) are uncorrected 
and were determined with a Reichert Kofler thermopan or in capillary tubes in a Büchi 
510 apparatus. 1H NMR (300 MHz) and 13C NMR (75.4 MHz) spectra were recorded 
with a Bruker AMX spectrometer using CDCl3 or DMSO-d6 as solvent. Chemical shifts 
(δ) are expressed in ppm using TMS as an internal standard. Coupling constants (J) 
are expressed in Hz. Spin multiplicities are given as s (singlet), d (doublet), dd (doublet 
of doublets), td (triplet of doublets) and m (multiplet). Mass spectrometry was carried 
out with a Hewlett-Packard-5972-MSD spectrometer. Elemental analyses were 
performed with a Perkin Elmer 240B microanalyzer and are within 0.4% of calculated 
values in all cases. Flash chromatography (FC) was performed on silica gel (Merck 60, 
230–400 mesh); analytical TLC was performed on pre-coated silica gel plates (Merck 
60 F254). Organic solutions were dried over anhydrous Na2SO4. Concentration and 
evaporation of the solvent after reaction or extraction was carried out on a rotary 
evaporator (Büchi Rotavapor) operating at reduced pressure. The analytical results 
showed > 95% purity for all compounds. 
Preparation of the precursor 3-amino-4-hydroxycoumarin. The commercially 
available 4-hydroxy-3-nitrocoumarin (2.5 mmol) was dissolved in ethanol and a 
catalytic amount of Pd/C was added to the mixture. The solution was stirred, at room 
temperature, under H2 atmosphere, for 5 h. After the completion of the reaction, the 
mixture was filtered to eliminate the catalyst. The obtained crude product was then 
purified by FC (hexane/ethyl acetate, 9:1) to give the desired coumarin, in a yield of 
90%. 
General procedure for the preparation of 3-amidocoumarins 1-17. The 3-
aminocoumarin (commercially available) or the 3-amino-4-hydroxycoumarin (1 mmol) 
was dissolved in dichloromethane (9 mL). Then, pyridine (1.1 mmol) was added and 
the mixture was cooled to 0 oC. Differently substituted acid chloride (1.1 mmol) was 
added drop-wise at this temperature, and the mixture was stirred overnight at room 
temperature. The batch was evaporated and purified by column chromatography 
(hexane/ethyl acetate, 9:1) to give the desired compounds 1-17. 
N-(4-Hydroxycoumarin-3-yl)-4’-methylbenzamide (3) Yield: 83%. Mp: 210-211 oC.1H 
NMR (DMSO-d6) δ (ppm), J (Hz): 2.49 (s, 3H, CH3), 7.31 (s, 1H, H-4), 7.37-7.44 (m, 
4H, H-6, H-8, H-3’, H-5’) 7.64-7.70 (m, 1H, H-7), 7.89-7.92 (m, 3H, H5, H-2’, H-6’), 9.47 
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(s, 1H, NH), 12.13 (s, 1H, OH). 13C NMR (DMSO-d6) δ (ppm): 21.0, 113.1, 116.2, 
116.3, 123.7, 124.3, 128.1, 128.8, 130.9, 132.4, 141.7, 151.6, 159.3, 160.4, 166.4. 
DEPT (DMSO-d6) δ (ppm): 21.0, 116.2, 123.7, 124.3, 128.1, 128.8, 132.4. MSm/z (%): 
296 (6), 295 (M+, 29), 119 (100), 91 (30), 65 (10). Ana. Elem. Calc. for C17H13NO4: C, 
69.15; H, 4.44. Found: C, 69.12; H, 4.42. 
N-(4-Hydroxycoumarin-3-yl)-3’,4’-dimethoxybenzamide (5) Yield: 88%. Mp: 247-
248 oC.1H NMR (DMSO-d6) δ (ppm), J (Hz): 3.82 (s, 6H, (CH3)2), 7.07 (d, 1H, H-5’, 
J=8.3), 7.40-7.45 (m, 2H, H-6, H-8) 7.59-7.69 (m, 3H, H-2’, H-6’, H-7), 7.90 (d, 1H, H-5, 
J=7.8), 9.44 (s, 1H, NH), 12.20 (s, 1H, OH).13C NMR (DMSO-d6) δ (ppm): 56.3, 103.9, 
111.5, 112.0, 116.9, 122.3, 124.3, 125.0, 126.6, 133.0, 148.8, 152.2, 152.4, 159.9, 
161.1, 166.8. DEPT (DMSO-d6) δ (ppm): 56.3, 111.5, 112.0, 116.9, 122.3, 124.3, 
125.0, 133.0. MSm/z (%): 342 (6), 341 (M+, 15), 323 (6), 165 (100), 121 (6), 92 (7), 77 
(9). Ana. Elem. Calc. for C18H15NO6: C, 63.34; H, 4.43. Found: C, 63.31; H, 4.41. 
N-(4-Hydroxycoumarin-3-yl)-3’,4’-dichlorobenzamide (8) Yield: 86%. Mp: 284-285 
oC.1H NMR (DMSO-d6) δ (ppm), J (Hz): 7.37-7.44 (m, 2H, H-6, H-8), 7.64-7.70 (m, 1H, 
H-5’) 7.79-7.96 (m, 3H, H-6’, H-5, H-7), 8.24 (s, 1H, H-2’), 9.78 (s, 1H, NH), 12.24 (s, 
1H, OH). 13C NMR (DMSO-d6) δ (ppm): 87.0, 116.5, 123.8, 123.9, 124.0, 124.5, 128.4, 
130.1, 130.8, 131.3, 132.7, 134.5, 150.5, 151.5, 160.1, 163.2. DEPT (DMSO-d6) δ 
(ppm): 116.5, 123.9, 124.0, 124.5, 128.4, 130.1, 130.8. MS m/z (%): 351 (54), 350 (M+, 
15), 349 (84), 333 (22), 331 (34), 175 (100), 174 (94), 147 (24), 145 (36), 121 (19), 111 
(14), 109 (14), 85 (17), 71 (19), 69 (14), 65 (14), 57 (19). Ana. Elem. Calc. for 
C16H9Cl2NO4: C, 54.88; H, 2.59. Found: C, 54.85; H, 2.55. 
N-(Coumarin-3-yl)furan-2-carboxamide (10) Yield: 90%. Mp: 183-184 oC.1H NMR 
(CDCl3): 6.74 (dd, 1H, H-4’, J=3.6, J=1.8), 7.34-7.58 (m, 4H, H-5, H-6, H-8, H-5’), 7.77 
(td, 1H, H-7, J=8.0, J=1.4), 8.00 (dd, 1H, H-3’, J=1.8, J=0.8), 8.58 (s, 1H, H-4), 9.26 (s, 
1H, NH). 13C NMR (CDCl3): 112.1, 113.2, 115.7, 116.8, 122.9, 124.3, 126.2, 126.8, 
127.7, 145.8, 146.5, 149.5, 155.3, 159.8. MS m/z (%): 256 (16), 255 (M+, 79), 227 (7), 
132 (6), 95 (100), 77 (10). Anal. Elem.Calc. for C14H9NO5: C, 62.00; H, 3.34. Found: C, 
62.03; H, 3.31. 
N-(4-Hydroxycoumarin-3-yl)cyclohexanecarboxamide (17) Yield: 91%. Mp: 199-200 
oC.1H NMR (CDCl3) δ (ppm), J (Hz): 1.17-1.69 (m, 6H, (CH2)3), 1.75-2.06 (m, 4H, 
(CH2)2), 2.30-2.55 (m, 1H, CH), 7.30-7.40 (m, 2H, H-6, H-8), 7.56(td, 1H, H-7, J=7.8, 
J=1.7),8.01 (dd, 1H, H-5, J=7.9, J=1.7), 8.28 (s, 1H, NH), 13.87 (s, 1H, OH).13C NMR 
(CDCl3) δ (ppm): 25.4, 25.7, 29.7, 45.5, 104.7, 116.2, 117.2, 124.4, 124.7, 131.6, 
150.5, 152.8, 161.2, 177.6. DEPT (DMSO-d6) δ (ppm): 25.4, 25.7, 29.7, 45.5, 116.2, 
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124.4, 124.7, 131.6. MS m/z (%): 288 (5), 287 (M+, 25), 177 (54), 121 (18), 111 (22), 
83 (100), 55 (43). Ana. Elem. Calc. for C16H17NO4: C, 66.89; H, 5.96. Found: C, 66.91; 
H, 5.99. 
Pharmacological assays 
Determination of MAO isoforms enzymatic activity 
The tested compounds were dissolved in DMSO (Sigma-Aldrich, Alcobendas, Madrid, 
Spain) to prepare 10 mM stock solutions, which were kept for storage at -20 oC. 
Percentage of DMSO used in the experiments was never higher than 1%. Selegiline 
and rasagiline, used as reference inhibitors, have been acquired from Sigma-Aldrich 
(Alcobendas, Madrid, Spain). Human recombinant MAO isoforms, used in the 
experiments, was purchased from Sigma-Aldrich (Alcobendas, Madrid, Spain). 
Resorufin sodium salt, p-tyramine hydrochloride, sodium phosphate buffer, horseradish 
peroxidase and Amplex® Red reagent has been supplied in the assay kit of Amplex® 
Red MAO Molecular Probes (Molecular Probes, Inc., Eugene, Oregon, USA). 
Briefly, 0.1 mL of sodium phosphate buffer (0.05 M, pH 7.4) containing different 
concentrations of the test drugs (new compounds or reference inhibitors) in various 
concentrations and adequate amounts of recombinant hMAO-A or hMAO-B required 
and adjusted to obtain in our experimental conditions the same reaction velocity, i.e., to 
oxidize (in the control group) the same concentration of substrate: 165 pmol of p-
tyramine/min (hMAO-A: 1.1 μg protein; specific activity: 150 nmol of p-tyramine 
oxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-B: 7.5 μg protein; 
specific activity: 22 nmol of p-tyramine transformed/min/mg protein) were incubated for 
15 min at 37 oC in a flat-black-bottom 96-well microtest plate, placed in the dark 
fluorimeter chamber. After this incubation period, the reaction was started by adding 
(final concentrations) 200 μM Amplex® Red reagent, 1 U/mL horseradish peroxidase 
and 1 mM p-tyramine. The production of H2O2 and, consequently, of resorufin was 
quantified at 37 oC in a multi detection microplate fluorescence reader (FLX800, Bio-
Tek Instruments, Inc., Winooski, VT, USA) based on the fluorescence generated 
(excitation, 545 nm, emission, 590 nm) over a 15 min period, in which the fluorescence 
increased linearly.[43] Control experiments were carried out simultaneously by replacing 
the test drugs (new compounds and reference inhibitors) with appropriate dilutions of 
the vehicles. In addition, the possible capacity of the above test drugs to modify the 
fluorescence generated in the reaction mixture due to non-enzymatic inhibition (e.g., for 
directly reacting with Amplex® Red reagent) was determined by adding these drugs to 
solutions containing only the Amplex® Red reagent in a sodium phosphate buffer. To 
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determine the kinetic parameters of hMAO-A and hMAO-B (Km and Vmax), the 
corresponding enzymatic activity of both isoforms was evaluated (under the 
experimental conditions described above) in the presence of a number (a wide range) 
of p-tyramine concentrations. 
The specific fluorescence emission (used to obtain the final results) was calculated 
after subtraction of the background activity, which was determined from wells 
containing all components except the hMAO isoforms, which were replaced by a 
sodium phosphate buffer solution. In our experimental conditions, this background 
activity was practically negligible. 
MAO activity of the test compounds and reference inhibitors is expressed as IC50, e.g. 
the concentration of each drug required to produce a 50% decreased on control value 
activity isoforms MAO. 
Determination of inhibition mode  
To evaluate whether compounds 1, 12, 14 and 17 are reversible or irreversible hMAO-
B inhibitors, a dilution method was used.[44] A 100x concentration of the enzyme used in 
the above described experiments was incubated with a concentration of inhibitor 
equivalent to 10-fold its IC50 value. After 30 min, the mixture was diluted 100-fold into 
reaction buffer containing Amplex Red reagent, horseradish peroxidase, and p-
tyramine, and the reaction was monitored for 15 min. Reversible inhibitors show linear 
progress with a slope equal to ~91% of the slope of the control sample, whereas 
irreversible inhibition reaches only ~9% of this slope. Control tests were carried out by 
pre-incubating and diluting the enzyme in the absence of inhibitor. 
Neuroprotective study 
DMSO, phosphate buffer pH 7.4 (PBS), Hanks buffer, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), H2O2 were acquired from Sigma-Aldrich, Química 
S.A., Alcobendas, Spain. Poly-D-lysine, neurobasal medium, L-glutamine, B-27 and 
fetal bovine serum (FBS) were acquired from Gibco/Invitrogen S.A., Barcelona, Spain. 
Primary culture of neurons and glia 
Pregnant rats (19-20 days) were killed by CO2 inhalation and embryos were 
immediately extracted from the womb by caesarean section and their brains were 
carefully dissected out. Meninges were removed and a portion of motor cortex was 
isolated after the dissection of the brain.[26] Fragments obtained from several embryos 
were subjected to mechanic disintegration. Neurobasal medium supplemented with 2% 
B-27 (for cortical neurons) was used to seed the cells in 96-well plates at a density of 
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100,000 cell/mL. Neuronal cultures were allowed to grow for 8-10 days keeping in an 
incubator (Form Direct Heat CO2, Thermo Electron Corporation, Madrid, Spain) under 
saturated humidity at a partial pressure of 5% CO2 in air at 37 
oC. 
Experiments were conducted on female Wistar Kyoto (WKY) rats, obtained from the rat 
colony maintained at the animal facilities of our department. Rats were housed, cared 
for and acclimatized (before the experiments). 
All experiments were carried out in accordance with European regulations on the 
protection of animals (Directive 2010/63/UE), the Spanish Real Decreto 53/2013 (1 
February) and/or the Guide for the Care and Use of Laboratory Animals as adopted 
and promulgated by the USA. 
Determination of the Neuronal Survival 
Neuronal cultures were treated with the compounds in the study at 100 µM 
concentration (final DMSO concentration ≤1%) or with studied compounds and H2O2 
(30 µM) over an incubation period of 24 hours. H2O2 was used as reference neurotoxic 
agents for neurons. 
Cell viability was determined to know the possible cytotoxicity of new compounds or 
their neuroprotective effects against a pro-oxidant (H2O2) agent, by reducing MTT to 
formazan by mitochondrias of viable cells. MTT (5 mg/mL in Hanks buffer) was added 
to each well to a final concentration of 10%.[52] 
After incubating for two hours at 37 °C, the medium was removed and formazan 
crystals formed were suspended in 100 µL/well of DMSO. The production of formazan 
by viable cells was quantified at 37 oC in a reader absorbance (Fluo-star Optima, BMG 
LABTECH, Offenburg, Germany) by determining the absorbance (570 nm).[53,54] 
In addition, the possible capacity of the above test drugs to modify the absorbance 
generated by reaction with MTT was determined by adding these drugs to solutions 
containing only MTT reagent in neurobasal medium. 
Determination of the neutralization of free radicals 
DMSO, DPPH, ascorbic acid and ethanol were acquired from Sigma-Aldrich Química 
S.A., Alcobendas, Spain. 
DPPH radical scavenging activity of each compound was determined as previously 
described with minor modifications. The DPPH radical was dissolved in ethanol (100 
µM) and 99 μL of the solutions were transferred to each well of a 96-well microplate. 1 
μL of compounds 3, 7, 9, 14 and 15 (100 μM, final concentration) in ethanol was added 
to each well of a 96 well microplate and the mixtures were incubated at room 
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temperature for 30 min. Vit. C (100 μM) was used as a positive control in the 
experiments. The absorbance at 540 nm was measured using a microplate reader. The 
scavenging activity of each compound was estimated by comparing the DPPH 
absorbance value in the antioxidant-radical reaction mixture after subtraction of the 
background activity.[55-57] 
In vitro blood-brain barrier permeation assay 
Hydrocortisone, desipramine, promazine, aldosterone, caffeine, ofloxacin, 
corticosterone, imipramine, testosterone, verapamil, piroxicam, lipid pig brain, 
phosphate buffered saline solution at pH 7.4 (PBS) and dodecane were purchased 
from Sigma-Aldrich Química S.A., Alcobendas, Spain and Acros, Madrid, Spain. 
Prediction of the brain penetration was evaluated using a PAMPA-BBB assay, in a 
similar manner as previously described.[46-49] Pipetting was performed with a semi-
automatic pipetter (CyBi®-SELMA) and UV reading with a microplate 
spectrophotometer (Multiskan Spectrum, Thermo Electron Co.). Millex filter units 
(PVDF membrane, diameter 25 mm, pore size 0.45 µm) were acquired from Millipore. 
The porcine brain lipid (PBL) was obtained from Avanti Polar Lipids. The donor 
microplate was a 96-well filter plate (PVDF membrane, pore size 0.45 µm) and the 
acceptor microplate was an indented 96-well plate, both from Millipore. The acceptor 
96 well microplate was filled with 200 µL of PBS:ethanol (70:30) and the filter surface of 
the donor microplate was impregnated with 4 mL of PBL in dodecane (20 mg mL-1). 
Compounds were dissolved in PBS: ethanol (70:30) at 10 µg mL-1, filtered through a 
Millex filter, and then added to the donor wells (200 µL). The donor filter plate was 
carefully put on the acceptor plate to form a sandwich, which was left undisturbed for 
240 min at 25 oC. After incubation, the donor plate is carefully removed and the 
concentration of compounds in the acceptor wells was determined by UV-Vis 
spectroscopy. Every sample is analyzed at five wavelengths, in four wells and at least 
in three independent runs, and the results are given as the mean ± standard deviation. 
In each experiment, 10 quality control standards of known BBB permeability were 
included to validate the analysis set. 
Theoretical evaluation of absorption, distribution, metabolism and excretion 
properties 
The absorption, distribution, metabolism and excretion (ADME) properties of the 
studied compounds were calculated using the Molinspiration property programme. 
LogP was calculated using the methodology developed by Molinspiration as a sum of 
fragment-based contributions and correction factors.[50] TPSA was calculated based on 
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the methodology published by Ertl et al. as a sum of fragment contributions.[58] 
Oxygenand nitrogen-centred polar fragments were considered.[50] PSA has been shown 
to be a very good descriptor characterizing drug absorption, including intestinal 
absorption, bioavailability, Caco-2 permeability and blood–brain barrier penetration. 
The method for calculation of molecule volume developed at Molinspiration is based on 
group contributions. These have been obtained by fitting the sum of fragment 
contributions to ‘real’ three dimensional (3D) volume for a training set of about 12,000, 
mostly drug-like molecules. 3D molecular geometries for a training set were fully 
optimized by the semi-empirical AM1 method. 
Statistics 
Results are expressed as mean of at least 3 experiments ± SEM or ± SD for blood-
brain barrier permeation assay. Statistically significant differences between two 
measurements (P <0.05, P <0.01 or P <0.001) were determined by analysis of 
variance (ANOVA) followed by the multiple comparison Dunnett's test. The graphical 
representation, the statistical analysis and calculation of IC50 values were performed 
using GraphPad Prism (V 4.03) software (San Diego, USA). 
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